Argenx

OncoVerity specializes in advancing targeted therapies for cancer. It focuses on optimizing the development of cusatuzumab, a novel anti-CD70 antibody.

Priority Review voucher is an e-marketing application for efgartigimod.

OncoVerity specializes in advancing targeted therapies for cancer. It focuses on optimizing the development of cusatuzumab, a novel anti-CD70 antibody.

Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of innovative therapies that target the extracellular matrix, particularly through its proprietary ENHANZE drug delivery technology. This technology utilizes a patented recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of various injectable biologics and small molecules. Halozyme’s product portfolio includes Hylenex recombinant, which aids in fluid administration and enhances the absorption of injected drugs. The company is advancing a range of product candidates for conditions such as breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and various autoimmune diseases. Additionally, Halozyme collaborates with major pharmaceutical companies to integrate its technology into therapeutic biologics. The company was founded in 1998 and operates internationally, primarily in the United States and Switzerland.